News

Odyssey Therapeutics Welcomes Jason Haas as CFO to Lead Growth

Odyssey Therapeutics Welcomes Jason Haas as CFO to Lead Growth

Odyssey Therapeutics Welcomes New CFO Jason Haas

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company aimed at revolutionizing treatment for autoimmune and inflammatory diseases, has recently appointed Jason Haas, MBA, as its chief financial officer. In this pivotal role, Mr. Haas is expected to utilize his vast experience in financial leadership to navigate the company through its growth trajectory.

Expertise in Financial Leadership

Jason Haas brings decades of financial experience to Odyssey, having formerly served as CFO for Syros Pharmaceuticals. His tenure there involved critical management of the finance group, strategic planning, and capital formation. His impressive history includes high-ranking positions at top-tier financial institutions like Barclays and Deutsche Bank, where he led Healthcare Investment Banking.

Significance of Mr. Haas' Appointment

Odyssey Therapeutics founder and CEO, Gary D. Glick, Ph.D., expressed enthusiasm about Mr. Haas joining the team. The addition of someone with such a strong background in financial leadership comes at a crucial time for the company, which is advancing a portfolio that includes small molecules and protein therapeutics. Dr. Glick noted the increasing complexity of the market and the importance of having seasoned experts to guide financial growth.

CFO's Vision for the Future

Upon his appointment, Mr. Haas shared his commitment to the company's mission to develop innovative medicines aimed at effectively managing autoimmune and inflammatory diseases. He underlined the importance of supporting the talented Odyssey team to execute on their groundbreaking scientific advancements.

Building a Robust Portfolio

Since its inception in 2021, Odyssey Therapeutics has made significant strides in developing a comprehensive pipeline of drug candidates. Mr. Haas aims to apply his financial expertise to empower the company in its quest for impactful therapeutic solutions.

About Odyssey Therapeutics

Odyssey Therapeutics is on a mission to improve patient outcomes by developing targeted therapies for autoimmune and inflammatory disorders. With a dedicated team of professionals, the company is leveraging innovative scientific insights to enhance its portfolio of product candidates, which they believe can lead to profound and lasting results for patients facing untreated medical needs.

Frequently Asked Questions

Who is the new CFO of Odyssey Therapeutics?

Jason Haas has been appointed as the new Chief Financial Officer of Odyssey Therapeutics.

What experience does Jason Haas bring to Odyssey Therapeutics?

He has extensive financial leadership experience from his previous roles, including his position as CFO at Syros Pharmaceuticals.

Why is Jason Haas' appointment significant?

His expertise in managing financial strategy is crucial for guiding Odyssey’s growth during an important phase of development.

What is the mission of Odyssey Therapeutics?

Odyssey aims to transform the standard of care for autoimmune and inflammatory diseases through targeted therapies.

When was Odyssey Therapeutics founded?

Odyssey Therapeutics was founded in 2021 and has rapidly built a portfolio to address unmet medical needs.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 159

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 92

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
ST Engineering iDirect, MBSat Forge Middle East Satellite Hub

Updated Category News Views 118

Satellite Services Take Off in the Middle East Never thought the day would come where the Middle East is on the threshold of leapfrogging satellite tech, but here we are. ST Engineering iDirect just locked arms with MBSat—yep, that's part of the Mohammed Al Barwani Group—to birth a next-gen satellite connectivity service hub in Oman and across surrounding areas....

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 158

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 145

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 98

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
What to Expect: Your First Therapy Session Insights

Updated Category News Views 201

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 0

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading

Top 5 Most Recently Viewed Articles

Jeff McLean Takes the Helm as ghSMART's New CEO

Updated Category News Views 620

Jeff McLean Takes the Helm as ghSMART's New CEO G.H. Smart & Company, LLC, the leading firm in leadership advisory, proudly announces the appointment of Jeff McLean as the Chief Executive Officer. McLean, who has been serving as President of ghSMART for three years, will now guide the firm towards its next exciting phase of growth and innovation. Achievements Under...

Continue Reading
Growth Forecast for Hot Dog and Sausage Market to 2032

Updated Category News Views 51

Introduction to the Hot Dog and Sausage Market The global market for hot dogs and sausages is witnessing a remarkable upward trajectory, with projections estimating it will reach USD 112.41 billion by 2032. This growth is fueled by a compound annual growth rate (CAGR) of 3.50%. The factors contributing to this expansion are numerous, including shifting consumer...

Continue Reading
Exro Technologies Adjusts Leadership with New CEO Plans

Updated Category News Views 337

Exro Technologies Announces Leadership Changes Exro Technologies Inc. has made a significant announcement regarding its leadership structure. Following the resignation of Sue Ozdemir from her role as Chief Executive Officer, the company has initiated steps to ensure a seamless transition and continuity in leadership. New Chief Restructuring Officer Appointed Introduction...

Continue Reading
Hillenbrand Increases Quarterly Dividend to $0.225 Per Share

Updated Category News Views 208

Hillenbrand's Exciting Dividend Announcement The board of directors of Hillenbrand, Inc. (NYSE: HI) has proudly announced a regular cash dividend of $0.225 per share on its common stock. This announcement signifies an annual increase of $0.01, bringing the total dividend rate to $0.90 per share for fiscal 2025. Such a commitment underlines Hillenbrand's dedication to...

Continue Reading
Trump's World Liberty Financial Token Sale Raises $220 Million

Updated Category News Views 113

Trump's World Liberty Financial Token Sale Demonstrates Huge Demand The World Liberty Financial project, closely associated with Donald Trump, made headlines recently as its token sale reached an impressive $220 million in just the first hour. Despite facing multiple outages on its website, the initiative showcased remarkable demand and interest. Details of the Token Sale...

Continue Reading